The recombinant Ebola virus vaccine obtained clinical approval within 20 days

The recombinant Ebola virus vaccine developed by the Institute of bioengineering, Academy of Military Medical Sciences, Chinese people's Liberation Army and Tianjin kangxinuo biotechnology was approved on February 25 The vaccine was declared in early February 2015, and only 20 days have passed since it was declared and approved This means that the Ebola vaccine developed in China has rapidly entered the clinical trial stage In July 2014, Ebola virus broke out again in West Africa, the severity of the epidemic is more serious than before, and the epidemic is still spreading According to the data of who official website, as of February 27, 2015, a total of 23825 people (including suspected cases) were infected with the Ebola virus haemorrhagic fever, of whom 9660 died Since the outbreak of Ebola virus, the global pharmaceutical giants and research institutions have focused on the research and development of anti Ebola virus vaccines and drugs The following is the research and development progress of anti Ebola drugs and vaccines in the world: This is a competition between human beings and dozens of nano Ebola viruses, as well as a competition between pharmaceutical companies in various countries In the research and development of Ebola virus drugs, Fuji company of Japan has the fastest pace Its favipiravir is considered to be one of the most promising drugs against Ebola virus, which is currently in phase II clinical trials Guinea decided to expand the use of favipiravir because of its positive results and the phenomenon of accelerating the recovery of patients In addition, in the summer of 2014, two medical rescuers in the United States received the treatment of zmapp, an antibody mixture experimental drug of MAPP biopharmaceutical Co., Ltd., and the symptoms were improved Therefore, the drug from tobacco plants became famous for a while At present, MAPP said it has prepared enough doses of drugs to carry out clinical trials in Liberia In the research and development of Ebola virus vaccine, GlaxoSmithKline's cad3-ebo vaccine is the most successful one Its early clinical trials show that the cad3-ebo vaccine is safe and immunogenic, without serious adverse reactions The results were published in the New England Journal of Medicine on November 27, 2014 Data from early clinical trials of the cad3 EBO vaccine give the government and pharmaceutical companies confidence to continue the next phase of trials In early February, the National Institutes of health of the United States, in cooperation with the Liberian health institutions, began to conduct large-scale trials of the rad3 EBO and the rvsv-zebov vaccines of MSD in Liberia to assess the safety and effectiveness of the two vaccines When the perspective turned back to China, China developed the five-year anti Ebola drug jk-05, which was approved by the army in August 2014 and shipped to Africa for use in emergencies Since then, the Institute of toxicants and drugs of Sihuan pharmaceutical and military academy has continued to cooperate in the development of fabiravir At present, the professional review of pharmacy has been completed, but the clinical trial approval has not yet been obtained In addition, the recombinant Ebola virus vaccine jointly developed by the Institute of bioengineering of the Academy of Military Sciences and Tianjin kangxinuo has obtained the approval for clinical research of special drugs in the army Recently, it has been approved by 20 Days to complete the review of normal pathway, recently approved clinical, the vaccine can be put into clinical trials in the shortest time, keeping pace with the global development of Ebola drugs and vaccines With the continuous spread of the Ebola epidemic, the research and development of Ebola drugs and vaccines are more urgent The investment of governments and pharmaceutical giants all over the world are looking forward to the results in the next one or two years, whether happy or sad, not only related to the rise and fall of the pharmaceutical companies' stock market, but also related to the global human health.